Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (91-100 of 252) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 23, 2004
The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5Hinrich P Hansen, Andreas Recke, Ulrich Reineke, et al.
Haematologica|January 23, 2025
Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphomaJulia Wendler, Richard I Lewis, Alexandra Kutilina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphomaRoland Schnell, Oliver Staak, Peter Borchmann, et al.
Blood|October 18, 2002
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphomaPeter Borchmann, Roland Schnell, Irene Fuss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
International Journal of Radiation Oncology, Biology, Physics|August 14, 2021
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 TrialChristian Baues, Helen Goergen, Michael Fuchs, et al.
The Cochrane Database of Systematic Reviews|September 13, 2021
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphomaMoritz Ernst, Annika Oeser, Burcu Besiroglu, et al.
International Journal of Cancer|July 9, 2004
Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivoBaerbel Matthey, Peter Borchmann, Roland Schnell, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2025
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphomaMarie Lommen, Jasmin J Weindler, Janina Jablonski, et al.
Pageof 26

Showing results (91-100 of 252) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 23, 2004
The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5Hinrich P Hansen, Andreas Recke, Ulrich Reineke, et al.
Haematologica|January 23, 2025
Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphomaJulia Wendler, Richard I Lewis, Alexandra Kutilina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphomaRoland Schnell, Oliver Staak, Peter Borchmann, et al.
Blood|October 18, 2002
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphomaPeter Borchmann, Roland Schnell, Irene Fuss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
International Journal of Radiation Oncology, Biology, Physics|August 14, 2021
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 TrialChristian Baues, Helen Goergen, Michael Fuchs, et al.
The Cochrane Database of Systematic Reviews|September 13, 2021
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphomaMoritz Ernst, Annika Oeser, Burcu Besiroglu, et al.
International Journal of Cancer|July 9, 2004
Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivoBaerbel Matthey, Peter Borchmann, Roland Schnell, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2025
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphomaMarie Lommen, Jasmin J Weindler, Janina Jablonski, et al.
Pageof 26